Evidence map›Paper›PMID 24860177›Full record

ArticleNeuro-oncology2014

Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model.

Isako Saga, Shunsuke Shibao, Jun Okubo, Satoru Osuka, Yusuke Kobayashi, Sachiko Yamada, Satoshi Fujita, Kenichi Urakami, Masatoshi Kusuhara, Kazunari Yoshida and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 46 citations in OpenAlex.

  1. Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Trial
  2. Review
  3. Frontiers in immunology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. New Immunotherapeutic Approaches for Glioblastoma.Journal of immunology research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Isako SagaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Shunsuke ShibaoDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Jun OkuboDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Satoru OsukaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Yusuke KobayashiDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Sachiko YamadaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Satoshi FujitaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Kenichi UrakamiDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Masatoshi KusuharaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Kazunari YoshidaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Hideyuki SayaDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Oltea SampetreanDivision of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Shizuoka Cancer Center · JPThe University of Tokyo · JPToho University · JPKeio University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe metabolic preference of malignant glioma for glycolysis as an energy source is a potential therapeutic target. As a result of the cellular heterogeneity of these tumors, however, the relation between glycolytic preference, tumor formation, and tumor cell clonogenicity has remained unknown. To address this issue, we analyzed the metabolic profiles of isogenic glioma-initiating cells (GICs) in a mouse model.

methodsGICs were established by overexpression of H-Ras(V12) in Ink4a/Arf-null neural stem cells. Subpopulations of these cells were obtained by single-cell cloning, and clones differing in extracellular acidification potential were assessed for metabolic characteristics. Tumors formed after intracranial implantation of these clones in mice were examined for pathological features of glioma and expression of glycolytic enzymes.

resultsMalignant transformation of neural stem cells resulted in a shift in metabolism characterized by an increase in lactic acid production. However, isogenic clonal populations of GICs manifested pronounced differences in glucose and oxygen consumption, lactate production, and nucleoside levels. These differences were paralleled by differential expression of glycolytic enzymes such as hexokinase 2 and pyruvate kinase M2, with this differential expression also being evident in tumors formed by these clones in vivo.

conclusionsThe metabolic characteristics of glioma cells appear early during malignant transformation and persist until the late stages of tumor formation. Even isogenic clones may be heterogeneous in terms of metabolic features, however, suggesting that a more detailed understanding of the metabolic profile of glioma is imperative for effective therapeutic targeting.

Indexed as

AnimalsBrain NeoplasmsCell DifferentiationCell Transformation, NeoplasticDisease Models, AnimalGlioblastomaHumansMiceNeoplastic Stem CellsTumor Cells, CulturedGICglioma-initiating cellglioma stem cellmetabolismWarburg effect

Identifiers

PMID24860177
PMCPMC4096179
OpenAlexW2146744576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.